Kyowa Kakko Kirin signs license agreement of hyperphosphatemia treatment ‘Nephoxil’
Kyowa Hakko Kirin Korea(CEO Shigeaki Suzuki) announced a license agreement of the hyperphosphatemia treatment ‘Nephoxil’ with Taiwanese Panion & BF Biotech on the 20th of February.
Hyperphosphatemia is a symptom in which there is an abnormally elevated level of phosphate in the blood for chronic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
